tas-117
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2017 (NCT03017521)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase AKT2INHIBITOR
AKT2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 3-amino-1-methyl-3-(4-(3-phenyl-5h- imidazo(1,2-c)pyrido(3,4-e)(1,3)oxazin-2-yl)phenyl)cyclobutanol
- tas-117
- tas-117
- tas-117
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04770246 | Phase 2 | Mar 31, 2021 | Otsuka |
| NCT03017521 | Phase 2 | Jan 1, 2017 | Yonsei University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otsuka | For profit | 1 | 1 | 1 | 2021 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1